FGFR2 is a Crucial Factor for Adipose‐Derived Mesenchymal Stem Cells in Promoting Diabetic Foot Ulcer Healing Through Angiogenesis

Jing Cao, Zichao Liu, Wenqiang An, Xin Zhang, Zhujun Li, Lijie Li, Hai-Lian Ji, Sen Zhang, Xiao Long, Yuemei YangJournal of Cellular and Molecular Medicine 2025 · DOI

TL;DR

This study reveals that adipose-derived mesenchymal stem cells (ADSCs) promote the healing of diabetic foot ulcers (DFUs) by upregulating FGFR2, which in turn activates a signaling cascade crucial for blood vessel formation (angiogenesis). This discovery sheds light on the underlying mechanisms of ADSC therapy and suggests FGFR2 as a potential therapeutic target for improving DFU outcomes.

What Problem Does This Paper Address?

Diabetic foot ulcers (DFUs) are a serious and common complication of diabetes, leading to significant morbidity, including amputation, and a reduced quality of life. Current treatments are often ineffective, and the underlying mechanisms of DFU pathogenesis and healing are not fully understood. While mesenchymal stem cells (MSCs), particularly adipose-derived stem cells (ADSCs), have shown promise in promoting DFU healing, the precise molecular pathways they utilize remain unclear. Specifically, the role of ADSCs in fostering the formation of new blood vessels (angiogenesis), a critical process for wound repair, and how they might influence key signaling molecules involved in this process, needed further investigation.

Methods

The researchers employed a multi-pronged approach combining bioinformatics analysis with experimental validation.

  • Bioinformatics Analysis: They analyzed gene expression data from two public datasets (GSE7014 and GSE80178) to identify differentially expressed genes (DEGs) in DFU patients compared to healthy controls. These DEGs were then intersected with a database of angiogenesis-related genes to pinpoint "angiogenesis-related DEGs" (An-DEGs).
  • Network and Machine Learning Analysis: A protein-protein interaction (PPI) network was constructed using the An-DEGs to identify "hub genes" – genes central to the network. Further refinement of these hub genes was achieved using four distinct machine learning algorithms (LASSO, SVM-RFE, Random Forest, and XGBoost) to pinpoint the most critical factors.
  • In Vitro Experiments: Human umbilical vein endothelial cells (HUVECs) were used to study the effects of ADSCs and their conditioned media on angiogenesis. Experiments included gene knockdown (using siRNA for FGFR2) and pathway inhibition (using a PI3K inhibitor) to dissect the signaling mechanisms.
  • In Vivo Experiments: A mouse model of diabetic foot ulcers was established to evaluate the therapeutic effects of ADSCs on wound healing, tissue regeneration, and angiogenesis markers.
  • Molecular Assays: Techniques like RT-qPCR, Western blotting, and ELISA were used to quantify gene and protein expression levels, as well as cytokine secretion.

Datasets

  • GSE7014 and GSE80178: Publicly available gene expression datasets from the Gene Expression Omnibus (GEO) database, used for identifying differentially expressed genes in DFU patients.
  • GeneCards: A database used to identify angiogenesis-related genes for intersection with DEGs.
  • STRING database and Cytoscape: Tools used for constructing and visualizing protein-protein interaction networks.

No new benchmarks were introduced in this study.

Key Insights and Ideas

  • FGFR2 as a Central Player: The study strongly implicates Fibroblast Growth Factor Receptor 2 (FGFR2) as a critical mediator of ADSC-driven DFU healing. Its downregulation in DFU patients and subsequent upregulation by ADSCs highlight its importance.
  • The FGF-PI3K/Akt-HIF-1α-VEGF Axis: ADSCs don't just boost FGFR2; they activate a specific signaling pathway downstream of it. This cascade, involving FGF, PI3K/Akt, HIF-1α, and VEGF, is a well-established route for promoting angiogenesis.
  • Dual Mechanism of ADSCs: ADSCs appear to work through a two-pronged strategy: they enhance the expression of FGFR2 in the wound environment and directly secrete FGF, creating a potent synergistic effect that amplifies angiogenesis.
  • Synergy with VEGF: Beyond the FGFR2 pathway, ADSCs also directly secrete VEGF, further contributing to their pro-angiogenic and wound-healing capabilities. This multifaceted approach likely explains their effectiveness.

Key Results

  • Bioinformatics analysis identified 35 angiogenesis-related differentially expressed genes (An-DEGs) in DFU patients.
  • Machine learning and network analysis pinpointed FGFR2, along with PGF and ANGPT1, as key genes associated with DFU angiogenesis.
  • FGFR2 expression was significantly downregulated in DFU patient datasets and in a DFU mouse model.
  • ADSC treatment in DFU mice led to:
  • Significantly upregulated Fgfr2 mRNA and protein expression in wound tissues.
  • Accelerated wound healing rates.
  • Increased collagen deposition.
  • Elevated levels of VEGF and increased microvessel density (CD31+ vessels).
  • Increased serum VEGF levels.
  • In vitro experiments showed that ADSCs promote FGFR2 expression in AGE-treated HUVECs (a model for diabetic conditions) and enhance their tube formation capacity.
  • Knockdown of FGFR2 or inhibition of the PI3K pathway abolished the pro-angiogenic effects of ADSCs on HUVECs, confirming the importance of the FGF-PI3K/Akt-HIF-1α-VEGF axis.
  • ADSCs were shown to secrete FGF and VEGF, with neutralizing antibodies against both significantly impairing HUVEC migration and tube formation.

Limitations and Future Work

The authors acknowledge several limitations:

  • Precise Mechanism of FGFR2 Upregulation: While they show ADSCs upregulate FGFR2, the exact molecular mechanisms by which ADSCs achieve this remain to be fully elucidated.
  • DFU Mouse Model Limitations: The current DFU mouse models may not perfectly recapitulate the complex chronic wound environment of human DFUs, as they tend to heal faster than human ulcers.
  • Future Directions: The authors plan to investigate the regulatory mechanisms of ADSC-induced FGFR2 expression further. They also aim to develop more suitable animal models that better mimic chronic human wound healing. Additionally, they suggest future studies could explore using splinting techniques and focus on elucidating the regulatory mechanisms of ADSCs-induced FGFR2 expression.

Summary updated

Abstract

Diabetic foot ulcers (DFUs) remain a significant clinical challenge due to the lack of effective treatments, severely impacting patients' quality of life. Mesenchymal stem cells (MSCs) have shown potential in promoting DFU healing; however, the underlying mechanisms are not yet fully understood. This study investigates the role of adipose-derived mesenchymal stem cells (ADSCs) in DFU healing, with a particular focus on angiogenesis. Gene expression profiles from the GSE7014 and GSE80178 datasets in the Gene Expression Omnibus (GEO) database were analyzed. Differentially expressed genes (DEGs) were intersected with angiogenesis-related genes from the GeneCards database, identifying 35 angiogenesis-related DEGs (An-DEGs). Key genes were selected using Cytoscape software and machine learning. The pro-angiogenic effects of ADSCs were validated through in vivo and in vitro experiments, assessing their role in DFU healing. The DEGs from DFU patients were enriched in pathways such as angiogenesis and collagen-containing extracellular matrix. ADSCs promoted angiogenesis and wound healing by upregulating FGFR2 and secreting FGF, activating the FGF-PI3K/Akt-HIF-1α-VEGF axis. Additionally, ADSCs mediated secretion of VEGF concerting this effect. FGFR2 plays a pivotal role in ADSCs' mediated DFU healing by driving angiogenesis.
BibTeX
@article{cao2025i,
  author = {Jing Cao and Zichao Liu and Wenqiang An and Xin Zhang and Zhujun Li and Lijie Li and Hai-Lian Ji and Sen Zhang and Xiao Long and Yuemei Yang},
  title = {{<i>FGFR2</i> is a Crucial Factor for Adipose‐Derived Mesenchymal Stem Cells in Promoting Diabetic Foot Ulcer Healing Through Angiogenesis}},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2025},
  doi = {10.1111/jcmm.70942},
}
Figure